
Forest plots for review question 1.1 For adults with depression, what are the relative benefits and harms associated with different models for the coordination and delivery of services?

Comparison 1: Collaborative care versus standard care/enhanced standard care

Critical outcomes

Figure 4: Depression symptomatology at 6 months



Test for subgroup differences: Not applicable

Figure 5: Depression symptomatology at 12 months




Figure 6: Response at 6 months




Figure 7: Response at 12 months




Figure 8: Remission at 6 months




Figure 9: Remission at 12 months

	Experim	ental	Control			Risk Ratio	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI		
1.6.1 Simple collabora	tive care								
Aragones 2012	84	198	46	162	9.1%	1.49 [1.11, 2.00]	-		
Bruce 2004	87	320	62	278	9.2%	1.22 [0.92, 1.62]	 -		
Chen 2015	63	164	9	162	4.8%	6.91 [3.56, 13.43]			
EII 2007	32	155	37	156	7.4%	0.87 [0.57, 1.32]			
Gensichen 2009	38	316	29	310	6.9%	1.29 [0.81, 2.03]	 -		
Harter 2018	115	610	12	169	5.7%	2.66 [1.50, 4.69]	_ 		
Katzelnick 2000	92	218	49	189	9.2%	1.63 [1.22, 2.17]			
Ludman 2007	13	26	15	26	6.4%	0.87 [0.52, 1.44]			
Ng 2020	55	135	47	139	8.9%	1.20 [0.88, 1.64]	 -		
Richards 2013/2016	131	276	106	305	10.3%	1.37 [1.12, 1.66]	+		
Wells 2000	342	913	144	443	10.7%	1.15 [0.98, 1.35]	<u>*</u> .		
Subtotal (95% CI)		3331		2339	88.5%	1.42 [1.16, 1.73]	◆		
Total events	1052		556						
Heterogeneity: Tau ² = 0 Test for overall effect: Z				P < 0.0I	0001); I² =	: 77%			
restior overall ellect. Z	.= 3.41 (F	- 0.000	()						
1.6.2 Complex collabo	rative car	е							
Holzel 2018	36	139	12	109	5.3%	2.35 [1.29, 4.30]			
Huijbregts 2013	12	101	2	49	1.5%	2.91 [0.68, 12.50]			
Morriss 2016	19	93	11	94	4.6%	1.75 [0.88, 3.46]			
Subtotal (95% CI)		333		252	11.5%	2.13 [1.38, 3.28]	•		
Total events	67		25						
Heterogeneity: Tau ² = 0).00; Chi² :	= 0.61, d	lf = 2 (P =	0.74);	I² = 0%				
Test for overall effect: Z	= 3.42 (P	= 0.000	6)						
Total (95% CI)		3664		2591	100.0%	1.49 [1.23, 1.80]	•		
Total events	1119		581						
Heterogeneity: Tau ² = 0		49.24.		P < 0.0I	0001); I² =	: 74%			
Test for overall effect: Z					,,,		0.01 0.1 1 10 100 Favours standard care Favours CC		
Test for subgroup diffe	•		•	P - n n	0) P = 64	7%	Favours standard care Favours CC		

Figure 10: Antidepressant use at 6 months





Figure 11: Antidepressant use at 12 months

	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
.8.1 Simple collaborative	care						
Aragones 2012	107	172	73	130	9.1%	1.11 [0.91, 1.34]	+
Bosanquet 2017	61	173	68	185	6.5%	0.96 [0.73, 1.26]	+
3ruce 2004	142	320	89	278	8.4%	1.39 [1.12, 1.71]	+
Capoccia 2004	24	41	19	33	4.3%	1.02 [0.69, 1.50]	+
Oobscha 2006	150	189	129	186	11.6%	1.14 [1.01, 1.29]	<u>*</u>
EII 2007	99	155	76	156	8.8%	1.31 [1.07, 1.60]	-
ensichen 2009	142	246	158	274	10.6%	1.00 [0.86, 1.16]	+
3ilbody 2017/Lewis 2017	23	234	44	281	3.2%	0.63 [0.39, 1.01]	
larjoura 2004	21	33	4	28	1.0%	4.45 [1.73, 11.44]	
udman 2007.	13	26	6	26	1.3%	2.17 [0.97, 4.82]	
Richards 2013/2016	164	235	182	263	11.7%	1.01 [0.90, 1.13]	†
Subtotal (95% CI)		1824		1840	76.6%	1.12 [0.99, 1.26]	*
otal events	946		848				
Heterogeneity: Tau ^z = 0.02;	Chi ² = 29.6	57, df = 1	0 (P = 0.	.001); l ^a	= 66%		
est for overall effect: Z = 1	.88 (P = 0.0	6)					
1 0 2 C							
i.8.2 Complex collaborativ	ле саге						l l
•	ve care 84	110	88	133	10.2%	1.15 [0.98, 1.35]	-
ortney 2007		110 889	88 497	133 870	10.2% 13.2%	1.15 [0.98, 1.35] 1.28 [1.19, 1.37]	•
ortney 2007 Jnutzer 2002/Arean 2005	84						;
1.8.2 Complex collaborativ Fortney 2007 Unutzer 2002/Arean 2005 Subtotal (95% CI) Fotal events	84	889		870	13.2%	1.28 [1.19, 1.37]	;
ortney 2007 Jnutzer 2002/Arean 2005 Subtotal (95% CI) Total events	84 649 733	889 999	497 585	870 1003	13.2% 23.4 %	1.28 [1.19, 1.37]	•
ortney 2007 Jnutzer 2002/Arean 2005 Subtotal (95% CI) Otal events Heterogeneity: Tau² = 0.00;	84 649 733 ; Chi² = 1.33	889 999 2, df = 1	497 585	870 1003	13.2% 23.4 %	1.28 [1.19, 1.37]	•
ortney 2007 Jnutzer 2002/Arean 2005 Subtotal (95% CI) Total events Heterogeneity: Tau² = 0.00 Test for overall effect: Z = 5	84 649 733 ; Chi² = 1.33	889 999 2, df = 1	497 585	870 1003 (i); I² = 2	13.2% 23.4 %	1.28 [1.19, 1.37]	
Fortney 2007 Unutzer 2002/Arean 2005 Subtotal (95% CI) Fotal events Heterogeneity: Tau² = 0.00; Fest for overall effect: Z = 5	84 649 733 ; Chi ^z = 1.32 .03 (P < 0.0	889 999 2, df = 1 0001)	497 585 (P = 0.25	870 1003 (i); I² = 2	13.2% 23.4% 4%	1.28 [1.19] 1.37] 1.25 [1.14, 1.36]	
ortney 2007 Unutzer 2002/Arean 2005 Subtotal (95% CI) Total events Heterogeneity: Tau² = 0.00; Test for overall effect: Z = 5 Total (95% CI) Total events	84 649 733 ; Chi² = 1.32 .03 (P < 0.0	889 999 2, df = 1 0001) 2823	497 585 (P = 0.25	870 1003 (); I ² = 2 2843	13.2% 23.4% 4% 100.0%	1.28 [1.19] 1.37] 1.25 [1.14, 1.36]	
ortney 2007 Jnutzer 2002/Arean 2005 Subtotal (95% CI) Total events Heterogeneity: Tau² = 0.00 Test for overall effect: Z = 5	84 649 733 ; Chi² = 1.32 .03 (P < 0.0 1679 ; Chi² = 39.9	889 999 2, df = 1 0001) 2823 38, df = 1	497 585 (P = 0.25	870 1003 (); I ² = 2 2843	13.2% 23.4% 4% 100.0%	1.28 [1.19] 1.37] 1.25 [1.14, 1.36]	0.01 0.1 10 100 Favours standard care Favours CC

Figure 12: Discontinuation at 6 months

	Experimental Control					Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.9.1 Simple collaborative of	care						
Aragones 2012	21	198	28	162	5.4%	0.61 [0.36, 1.04]	-
Araya 2003	16	120	13	120	4.2%	1.23 [0.62, 2.45]	
Bjorkelund 2018	49	196	37	189	6.6%	1.28 [0.88, 1.86]	
Buszewicz 2016	81	282	109	276	7.7%	0.73 [0.58, 0.92]	-
Chen 2015	42	164	45	162	6.7%	0.92 [0.64, 1.32]	+
Curth 2020	68	272	10	53	4.9%	1.32 [0.73, 2.40]	+-
Finley 2003	16	75	25	50	5.4%	0.43 [0.25, 0.71]	
Harter 2018	249	610	55	169	7.7%	1.25 [0.99, 1.59]	 -
Huang 2018	34	139	39	141	6.4%	0.88 [0.60, 1.31]	-
Jeong 2013	1	29	2	28	0.7%	0.48 [0.05, 5.03]	
Ng 2020	36	135	40	139	6.5%	0.93 [0.63, 1.36]	-
Oladeji 2015	28	165	5	69	3.1%	2.34 [0.94, 5.81]	
Simon 2004 (CM)	12	207	16	88	4.1%	0.32 [0.16, 0.65]	
Simon 2006	14	103	10	104	3.8%	1.41 [0.66, 3.04]	+-
Smit 2006	31	195	10	72	4.4%	1.14 [0.59, 2.21]	
Wells 2000	143	913	57	443	7.3%	1.22 [0.92, 1.62]	}-
Subtotal (95% CI)		3803		2265	84.8%	0.94 [0.77, 1.14]	•
Total events	841		501				
Heterogeneity: Tau² = 0.09;			15 (P = 0.	0001);	l² = 66%		
Test for overall effect: $Z = 0.6$	31 (P = 0.5	4)					
1.9.2 Complex collaborative	e care						
Huijbreats 2013	38	101	10	49	4.8%	1.84 [1.00, 3.38]	
Simon 2004 (CM + psych)	9	198	16	88	3.7%	0.25 [0.11, 0.54]	
Unutzer 2002/Arean 2005	64	906	49	895	6.7%	1.29 [0.90, 1.85]	-
Subtotal (95% CI)	04	1205	43	1032	15.2%	0.88 [0.33, 2.31]	-
Total events	111		75				
Heterogeneity: Tau ² = 0.64;	$Chi^2 = 17.4$	9. df = 2	2 (P = 0.0)	002): l²	= 89%		
Test for overall effect: Z = 0.2	26 (P = 0.7	9)	•				
Total (95% CI)		5008		3297	100.0%	0.94 [0.77, 1.15]	•
Total events	952		576]
Heterogeneity: Tau ^z = 0.12;		.4 df = 1		00001	· 2 = 71 %	1	
Test for overall effect: $Z = 0.5$				23001)	, . = x	•	0.01 0.1 1 10 100
Test for subgroup difference	•		1 (P = 0	89) /*:	= 0%		Favours CC Favours standard care
. SS. for Sabaroap afficience	o – c	ai -	. ,, = 0	.507, 1	570		


Figure 13: Discontinuation at 12 months



Comparison 2: Collaborative care versus standard care for relapse prevention

Critical outcomes

Figure 14: Relapse at 12 months



220

Figure 15: Antidepressant use at 6 months




Figure 16: Antidepressant use at 12 months





Figure 17: Discontinuation at 12 months



Test for subgroup differences: Not applicable

Comparison 3: Stepped care versus standard care/enhanced standard care

Figure 18: Depression symptomatology endpoint score at 6 months




Figure 19: Depression symptomatology change score at 6 months

Expe	rimen	tal	C	ontrol			Std. Mean Difference		Std. Mean Difference		
Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	d, 95% CI	
-8.27	3.19	417	-4.42	3.3	199	69.2%	-1.19 [-1.37, -1.01]				
-1.1	6.31	107	-2.9	5.89	103	30.8%	0.29 [0.02, 0.57]			•	
		524			302	100.0%	-0.73 [-0.89, -0.58]		•		
Heterogeneity: Chi² = 79.26, df = 1 (P < 0.00001); l² = 99% Test for overall effect: Z = 9.53 (P < 0.00001)								-10	-5	5	10
	-8.27 -1.1	Mean SD -8.27 3.19 -1.1 6.31 3.26, df = 1 (P	-8.27 3.19 417 -1.1 6.31 107 524 3.26, df=1 (P < 0.000	Mean SD Total Mean -8.27 3.19 417 -4.42 -1.1 6.31 107 -2.9 524 3.26, df = 1 (P ≤ 0.00001); F =	Mean SD Total Mean SD -8.27 3.19 417 -4.42 3.3 -1.1 6.31 107 -2.9 5.89 524 3.26, df = 1 (P < 0.000 01); P = 99%	Mean SD Total Mean SD Total -8.27 3.19 417 -4.42 3.3 199 -1.1 6.31 107 -2.9 5.89 103 524 302 3.26, df = 1 (P < 0.000 01); F = 99%	Mean SD Total Mean SD Total Weight -8.27 3.19 417 -4.42 3.3 199 69.2% -1.1 6.31 107 -2.9 5.89 103 30.8% 524 302 100.0% 3.26, df = 1 (P < 0.00001); F = 99%	Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI -8.27 3.19 417 -4.42 3.3 199 69.2% -1.19 [-1.37, -1.01] -1.1 6.31 107 -2.9 5.89 103 30.8% 0.29 [0.02, 0.57] 524 302 100.0% -0.73 [-0.89, -0.58] 3.26, df = 1 (P < 0.00001); F = 99%	Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI -8.27 3.19 417 -4.42 3.3 199 69.2% -1.19 [-1.37, -1.01] -1.1 6.31 107 -2.9 5.89 103 30.8% 0.29 [0.02, 0.57] 524 302 100.0% -0.73 [-0.89, -0.58] 3.26, df = 1 (P < 0.00001); ² = 99%	Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed -8.27 3.19 417 -4.42 3.3 199 69.2% -1.19 [-1.37, -1.01] -1.19 [-1.37, -1.01] -1.1 6.31 107 -2.9 5.89 103 30.8% 0.29 [0.02, 0.57] 524 302 100.0% -0.73 [-0.89, -0.58] -10 -5 -9.53 (P < 0.00001)	Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI -8.27 3.19 417 -4.42 3.3 199 69.2% -1.19 [-1.37, -1.01] ■ -1.1 6.31 107 -2.9 5.89 103 30.8% 0.29 [0.02, 0.57] 3.26, df = 1 (P < 0.00001); P = 99%

Figure 20: Depression symptomatology endpoint score at 12 months

	Exper	rimen	tal	Co	ontro	I	Std. Mean Difference			Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed	I, 95% CI	
Gureje 2019	3.6	4.9	542	3.5	3.9	456	100.0%	0.02 [-0.10, 0.15]				
Total (95% CI)	ماطممناهم		542			456	100.0%	0.02 [-0.10, 0.15]			,	
Heterogeneity: Not ap Test for overall effect:		(P = 0).73)						-10	-5 Favours stepped care) 5 Favours standard care	10

Figure 21: Depression symptomatology change score at 12 months

	Expe	erimen	tal	C	ontrol		Std. Mean Difference			Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixed	d, 95% CI		
Van Der Weele 2012	-3.1	6.13	101	-4.6	6.17	93	100.0%	0.24 [-0.04, 0.53]					
Total (95% CI)			101			93	100.0%	0.24 [-0.04, 0.53]			•		
Heterogeneity: Not app Test for overall effect: 2		(P = 0.1	09)						-10	-5 Favours stepped care	0 5 Favours standard care	10	

Figure 22: Response at 6 months




Figure 23: Response at 12 months




Figure 24: Remission at 6 months




Figure 25: Remission at 12 months

	Experim	ental	Conti	rol		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI			
Adewuya 2019	275	456	82	451	49.7%	3.32 [2.69, 4.09]			-		
Gureje 2019	481	631	420	547	50.3%	0.99 [0.93, 1.06]			•		
Total (95% CI)		1087		998	100.0%	1.81 [0.45, 7.28]		-			
Total events	756		502								
Heterogeneity: $Tau^2 = 1.00$; $Chi^2 = 161.84$, $df = 1$ (P < 0.00001); $I^2 = 99\%$								0.1	 	10	100
Test for overall effect: Z = 0.83 (P = 0.40)								Favours standard care	Favours ste	pped care	100

Important outcomes

Figure 26: Antidepressant use at 6 months




Figure 27: Discontinuation at 6 months






Figure 28: Discontinuation at 12 months



Comparison 4: Stepped care versus standard care for relapse prevention

Critical outcomes

Figure 29: Relapse at 12 months



Important outcomes

Figure 30: Antidepressant use at 12 months





Figure 31: Discontinuation at 12 months



Comparison 5: Pure medication management versus standard care

Figure 32: Depression symptomatology at 6 months




Figure 33: Response at 6 months

	Experime	ental	Contr	rol		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Sirey 2010	14	33	8	37	100.0%	1.96 [0.94, 4.08]	-			
Total (95% CI)		33		37	100.0%	1.96 [0.94, 4.08]	•			
Total events	14		8							
Heterogeneity: Not ap Test for overall effect:	•	P = 0.07)				0.01 0.1 10 100 Favours standard care Favours MM			

Figure 34: Antidepressant use at 6 months





Figure 35: Discontinuation at 6 months



Comparison 6: Care coordination versus standard care/enhanced standard care

Figure 36: Depression symptomatology at 6 months




Figure 37: Depression symptomatology at 12 months

	Exper	rimen	tal	Co	ontro	I		Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	I, 95% CI	
Salisbury 2016	11.6	6.2	255	11.9	6.4	261	100.0%	-0.05 [-0.22, 0.13]			
Total (95% CI)			255			261	100.0%	-0.05 [-0.22, 0.13]			
Heterogeneity: Not ap Test for overall effect:		(P = 0	1.59)						-10 -5 (Favours care coordination) 5 Favours standard care	10

Figure 38: Remission at 12 months

	Experim	ental	Conti	rol		Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		N	1-H, Fixed, 95% (CI	
Salisbury 2016	95	307	86	302	100.0%	1.09 [0.85, 1.39]					
Total (95% CI)		307		302	100.0%	1.09 [0.85, 1.39]			•		
Total events	95		86								
Heterogeneity: Not ap Test for overall effect		P = 0.51)				0.01	0.1 Favours standa	1 Ird care Favour	10 s care coordina	100

Important outcomes

Figure 39: Discontinuation at 6 months





Figure 40: Discontinuation at 12 months



Comparison 7: Attached professional model versus enhanced standard care

Figure 41: Depression symptomatology at 6 months





Figure 42: Discontinuation at 6 months



Comparison 8: Shared care versus standard care

Critical outcomes

Figure 43: Depression symptomatology at 6 months





Figure 44: Remission at 6 months



Important outcomes

Figure 45: Antidepressant use at 6 months



Figure 46: Discontinuation at 6 months



Comparison 9: Measurement-based care versus standard care

Critical outcomes

Figure 47: Depression symptomatology at 6 months




Figure 48: Response at 6 months





Figure 49: Remission at 6 months



Important outcomes

Figure 50: Discontinuation at 6 months

